New International Pharma Industry Leader Brings Prospect Of Change

By William New
Alicia Greenidge represents a change for the global pharmaceutical and biotechnology industry, but as she grows into her role as the head of the industry's international trade association, it is unclear whether there will be substantive changes on policy relating to intellectual property and public health. Key policy areas include counterfeit medicines and funding for research and development into diseases afflicting poor populations in ways that echo past industry approaches, but Greenidge brings a new focus on networking and negotiation.

Counterfeit Medication, R&D Financing Key IP Issues At WHO Board Meeting

By Kaitlin Mara The Executive Board of the World Health Organization meets next week with significant discussion expected on a new secretariat report on counterfeit medical products as well as on the implementation of the WHO’s mandated global strategy on…

IP From Publicly Funded Research Should Benefit The Public, Experts Say

By Catherine Saez Publicly funded research institutions are major players in the area of life sciences and policies on the management of intellectual property emanating from this research have to be defined, according to speakers at a recent symposium in…